Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024

Apr 11, 2024

Shanghai, China, and Heidelberg, Germany – April 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, announced that the company has presented the preclinical data of 225Ac-FL-020 (a PSMA-targeted RDC program) at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.


“Using our proprietary Clear-X™ technology platform, we discovered 225Ac-FL-020, a novel 225Ac-based PSMA radioligand therapy candidate”, said Dr. Fa Liu, Chief Scientific Officer of Full-Life Technologies. “FL-020 has a unique chemical design that is differentiated from all other PSMA ligands, and it potently and selectivity binds to PSMA protein on tumor cell surface. Radiolabeled FL-020 displays a very promising in vivo biodistribution profile with high and sustained tumor uptake and fast systemic clearance in the preclinical models. 225Ac-FL-020 exhibits robust anti-tumor activity in the LNCaP xenograft mice with a favorable safety profile. The fast advancement of 225Ac-FL-020 towards a Phase I clinical trial in 2024 demonstrates our confidence in our Clear-X™ technology platform. Full-Life will continue and expand our efforts of developing novel RDC drug candidates for patients with unmet medical needs.”


Poster Session Presentation Details

Title: 225Ac-FL-020 is a novel PSMA-targeting radionuclide drug conjugate (RDC) with superior in vivo anti-tumor activity

Session Category: Experimental and Molecular Therapeutics

Session Title: Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress

Session Date and Time: Tuesday, Apr 9, 2024, 1:30 PM - 5:00 PM

Location: Poster Section 29

Poster Board Number: 5

Published Abstract Number: 6023

Full Texts of the Abstracts: https://www.abstractsonline.com/pp8/#!/20272/presentation/7532

Poster Details: https://www.full-life.com/Public/Uploads/uploadfile/files/20240410/AACRposterforFL020V2-456.pdf


About 225Ac-FL-020

225Ac-FL-020 is a novel, potential best-in-class next-generation PSMA-targeting radionuclide drug conjugate (RDC) currently being developed for the treatment of mCRPC and expected to enter global Ph1 clinical studies in H1 2024. Its targeting vector, FL-020, was discovered using Full-Life's proprietary Clear-X™ technology, which enables significant improvement of drug uptake in the tumor while maintaining fast systemic clearance. In pre-clinical models, 225Ac-FL-020 has demonstrated potent anti-tumor activity and a favorable safety profile.


About Full-Life Technologies

Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.


About AACR

The American Association for Cancer Research (AACR) was founded in 1907. The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. The AACR has more than 50,000 members residing in 129 countries and territories. Membership includes 256 Fellows of the AACR Academy and 54 Nobel laureates. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

For the Media

We welcome media inquiries. Please indicate your deadline on the subject line.